6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
also O
discussed O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Increased O
risk O
of O
stroke B-NonOSE_AE
after O
discontinuation O
in O
nonvalvular B-Not_AE_Candidate
atrial I-Not_AE_Candidate
fibrillation I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Bleeding B-OSE_Labeled_AE
risk O
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
, O
5.4 O
, O
5.5 O
, O
5.6 O
, O
5.7 O
) O
] O
* O
Spinal B-OSE_Labeled_AE
/epidural O
hematoma I-OSE_Labeled_AE
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
EXCERPT O
: O
The O
most O
common O
adverse O
reaction O
( O
> O
5 O
% O
) O
was O
bleeding O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Pharmaceuticals O
, O
Inc O
. O
at O
1-800-526-7736 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

During O
clinical O
development O
for O
the O
approved O
indications O
, O
18560 O
patients O
were O
exposed O
to O
XARELTO O
. O

These O
included O
7111 O
patients O
who O
received O
XARELTO O
15 O
mg O
or O
20 O
mg O
orally O
once O
daily O
for O
a O
mean O
of O
19 O
months O
( O
5558 O
for O
12 O
months O
and O
2512 O
for O
24 O
months O
) O
to O
reduce O
the O
risk O
of O
stroke B-Not_AE_Candidate
and O
systemic B-Not_AE_Candidate
embolism I-Not_AE_Candidate
in O
nonvalvular B-Not_AE_Candidate
atrial I-Not_AE_Candidate
fibrillation I-Not_AE_Candidate
( O
ROCKET O
AF O
) O
; O
6962 O
patients O
who O
received O
XARELTO O
15 O
mg O
orally O
twice O
daily O
for O
three O
weeks O
followed O
by O
20 O
mg O
orally O
once O
daily O
to O
treat O
DVT B-Not_AE_Candidate
or O
PE B-Not_AE_Candidate
( O
EINSTEIN O
DVT B-Not_AE_Candidate
, O
EINSTEIN O
PE B-Not_AE_Candidate
) O
, O
10 O
mg O
or O
20 O
mg O
orally O
once O
daily O
( O
EINSTEIN O
Extension O
, O
EINSTEIN O
CHOICE O
) O
to O
reduce O
the O
risk O
of O
recurrence O
of O
DVT B-Not_AE_Candidate
and/or O
PE B-Not_AE_Candidate
; O
and O
4487 O
patients O
who O
received O
XARELTO O
10 O
mg O
orally O
once O
daily O
for O
prophylaxis O
of O
DVT B-Not_AE_Candidate
following O
hip O
or O
knee O
replacement O
surgery O
( O
RECORD O
1-3 O
) O
. O

Hemorrhage B-OSE_Labeled_AE
The O
most O
common O
adverse O
reactions O
with O
XARELTO O
were O
bleeding B-OSE_Labeled_AE
complications I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
. O

Nonvalvular B-Not_AE_Candidate
Atrial I-Not_AE_Candidate
Fibrillation I-Not_AE_Candidate
In O
the O
ROCKET O
AF B-Not_AE_Candidate
trial O
, O
the O
most O
frequent O
adverse O
reactions O
associated O
with O
permanent O
drug O
discontinuation O
were O
bleeding B-OSE_Labeled_AE
events O
, O
with O
incidence O
rates O
of O
4.3 O
% O
for O
XARELTO O
vs O
. O
3.1 O
% O
for O
warfarin O
. O

The O
incidence O
of O
discontinuations O
for O
non B-NonOSE_AE
- I-NonOSE_AE
bleeding I-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
was O
similar O
in O
both O
treatment O
groups O
. O

Table O
1 O
shows O
the O
number O
of O
patients O
experiencing O
various O
types O
of O
bleeding B-NonOSE_AE
events O
in O
the O
ROCKET O
AF B-Not_AE_Candidate
trial O
. O

Table O
1 O
: O
Bleeding O
Events O
in O
ROCKET O
AFMajor O
bleeding O
events O
within O
each O
subcategory O
were O
counted O
once O
per O
patient O
, O
but O
patients O
may O
have O
contributed O
events O
to O
multiple O
subcategories O
. O

These O
events O
occurred O
during O
treatment O
or O
within O
2 O
days O
of O
stopping O
treatment.- O
On O
Treatment O
Plus O
2 O
Days O
Parameter O
XARELTON=7111n O
( O
% O
/year O
) O
WarfarinN=7125n O
( O
% O
/year O
) O
XARELTO O
vs O
. O
WarfarinHR O
( O
95 O
% O
CI O
) O
Abbreviations O
: O
HR O
= O
Hazard O
Ratio O
, O
CI O
= O
Confidence O
interval O
, O
CRNM O
= O
Clinically O
Relevant O
Non-Major O
. O

Major O
Bleeding B-OSE_Labeled_AE
[ O
note O
: O
Defined O
as O
clinically O
overt O
bleeding B-OSE_Labeled_AE
associated O
with O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
of O
> O
=2 O
g/dL O
, O
a O
transfusion O
of O
> O
=2 O
units O
of O
packed O
red O
blood O
cells O
or O
whole O
blood O
, O
bleeding B-OSE_Labeled_AE
at O
a O
critical O
site O
, O
or O
with O
a O
fatal O
outcome O
. O
] O

395 O
( O
3.6 O
) O
386 O
( O
3.5 O
) O
1.04 O
( O
0.90 O
, O
1.20 O
) O
Intracranial B-OSE_Labeled_AE
Hemorrhage I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ICH I-OSE_Labeled_AE
) O
[ O
note O
: O
Intracranial B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
events I-OSE_Labeled_AE
included O
intraparenchymal O
, O
intraventricular O
, O
subdural O
, O
subarachnoid B-OSE_Labeled_AE
and/or O
epidural O
hematoma I-OSE_Labeled_AE
. O
] O

55 O
( O
0.5 O
) O
84 O
( O
0.7 O
) O
0.67 O
( O
0.47 O
, O
0.93 O
) O
Hemorrhagic B-OSE_Labeled_AE
Stroke I-OSE_Labeled_AE
[ O
note O
: O
Hemorrhagic B-OSE_Labeled_AE
stroke I-OSE_Labeled_AE
in O
this O
table O
specifically O
refers O
to O
non-traumatic O
intraparenchymal B-OSE_Labeled_AE
and/or O
intraventricular O
hematoma I-OSE_Labeled_AE
in O
patients O
on O
treatment O
plus O
2 O
days O
. O
] O

36 O
( O
0.3 O
) O
58 O
( O
0.5 O
) O
0.63 O
( O
0.42 O
, O
0.96 O
) O
Other O
ICH B-OSE_Labeled_AE
19 O
( O
0.2 O
) O
26 O
( O
0.2 O
) O
0.74 O
( O
0.41 O
, O
1.34 O
) O
Gastrointestinal B-OSE_Labeled_AE
( I-OSE_Labeled_AE
GI I-OSE_Labeled_AE
) O
[ O
note O
: O
Gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
events O
included O
upper B-OSE_Labeled_AE
GI I-OSE_Labeled_AE
, O
lower O
GI O
, O
and O
rectal O
bleeding I-OSE_Labeled_AE
. O
] O

221 O
( O
2.0 O
) O
140 O
( O
1.2 O
) O
1.61 O
( O
1.30 O
, O
1.99 O
) O
Fatal O
Bleeding B-OSE_Labeled_AE
[ O
note O
: O
Fatal O
bleeding B-OSE_Labeled_AE
is O
adjudicated O
death O
with O
the O
primary O
cause O
of O
death O
from O
bleeding B-OSE_Labeled_AE
. O
] O

27 O
( O
0.2 O
) O
55 O
( O
0.5 O
) O
0.50 O
( O
0.31 O
, O
0.79 O
) O
ICH B-OSE_Labeled_AE
24 O
( O
0.2 O
) O
42 O
( O
0.4 O
) O
0.58 O
( O
0.35 O
, O
0.96 O
) O
Non-intracranial O
3 O
( O
0.0 O
) O
13 O
( O
0.1 O
) O
0.23 O
( O
0.07 O
, O
0.82 O
) O
Figure O
1 O
shows O
the O
risk O
of O
major O
bleeding B-NonOSE_AE
events O
across O
major O
subgroups O
. O

Figure O
1 O
: O
Risk O
of O
Major O
Bleeding O
Events O
by O
Baseline O
Characteristics O
in O
ROCKET O
AF O
- O
On O
Treatment O
Plus O
2 O
Days O
Note O
: O
The O
figure O
above O
presents O
effects O
in O
various O
subgroups O
all O
of O
which O
are O
baseline O
characteristics O
and O
all O
of O
which O
were O
pre-specified O
( O
diabetic B-NonOSE_AE
status O
was O
not O
pre-specified O
in O
the O
subgroup O
, O
but O
was O
a O
criterion O
for O
the O
CHADS2 O
score O
) O
. O

The O
95 O
% O
confidence O
limits O
that O
are O
shown O
do O
not O
take O
into O
account O
how O
many O
comparisons O
were O
made O
, O
nor O
do O
they O
reflect O
the O
effect O
of O
a O
particular O
factor O
after O
adjustment O
for O
all O
other O
factors O
. O

Apparent O
homogeneity O
or O
heterogeneity O
among O
groups O
should O
not O
be O
over-interpreted O
. O

Figure O
1 O
Treatment O
of O
Deep O
Vein O
Thrombosis O
( O
DVT O
) O
and/or O
Pulmonary O
Embolism O
( O
PE O
) O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
Studies O
In O
the O
pooled O
analysis O
of O
the O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
clinical O
studies O
, O
the O
most O
frequent O
adverse O
reactions O
leading O
to O
permanent O
drug O
discontinuation O
were O
bleeding B-OSE_Labeled_AE
events O
, O
with O
XARELTO O
vs O
. O
enoxaparin/Vitamin O
K O
antagonist O
( O
VKA O
) O
incidence O
rates O
of O
1.7 O
% O
vs O
. O
1.5 O
% O
, O
respectively O
. O

The O
mean O
duration O
of O
treatment O
was O
208 O
days O
for O
XARELTO-treated O
patients O
and O
204 O
days O
for O
enoxaparin/VKA-treated O
patients O
. O

Table O
2 O
shows O
the O
number O
of O
patients O
experiencing O
major O
bleeding B-NonOSE_AE
events O
in O
the O
pooled O
analysis O
of O
the O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
studies O
. O

Table O
2 O
: O
Bleeding O
EventsBleeding O
event O
occurred O
after O
randomization O
and O
up O
to O
2 O
days O
after O
the O
last O
dose O
of O
study O
drug O
. O

Although O
a O
patient O
may O
have O
had O
2 O
or O
more O
events O
, O
the O
patient O
is O
counted O
only O
once O
in O
a O
category O
. O

in O
the O
Pooled O
Analysis O
of O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
Studies O
Parameter O
XARELTO O
[ O
note O
: O
Treatment O
schedule O
in O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
studies O
: O
XARELTO O
15 O
mg O
twice O
daily O
for O
3 O
weeks O
followed O
by O
20 O
mg O
once O
daily O
; O
enoxaparin/VKA O
[ O
enoxaparin O
: O
1 O
mg/kg O
twice O
daily O
, O
VKA O
: O
individually O
titrated O
doses O
to O
achieve O
a O
target O
INR O
of O
2.5 O
( O
range O
: O
2.0-3.0 O
) O
] O
] O
N=4130n O
( O
% O
) O
Enoxaparin/VKAN=4116n O
( O
% O
) O
Major O
bleeding B-OSE_Labeled_AE
event O
40 O
( O
1.0 O
) O
72 O
( O
1.7 O
) O
Fatal O
bleeding B-OSE_Labeled_AE
3 O
( O
< O
0.1 O
) O
8 O
( O
0.2 O
) O
Intracranial O
2 O
( O
< O
0.1 O
) O
4 O
( O
< O
0.1 O
) O
Non-fatal O
critical O
organ O
bleeding B-OSE_Labeled_AE
10 O
( O
0.2 O
) O
29 O
( O
0.7 O
) O
Intracranial B-OSE_Labeled_AE
[ O
note O
: O
Treatment-emergent O
major O
bleeding I-OSE_Labeled_AE
events O
with O
at O
least O
> O
2 O
subjects O
in O
any O
pooled O
treatment O
group O
] O
3 O
( O
< O
0.1 O
) O
10 O
( O
0.2 O
) O
Retroperitoneal O
1 O
( O
< O
0.1 O
) O
8 O
( O
0.2 O
) O
Intraocular O
3 O
( O
< O
0.1 O
) O
2 O
( O
< O
0.1 O
) O
Intra-articular O
0 O
4 O
( O
< O
0.1 O
) O
Non-fatal O
non-critical O
organ O
bleeding B-OSE_Labeled_AE
[ O
note O
: O
Major O
bleeding B-OSE_Labeled_AE
which O
is O
not O
fatal O
or O
in O
a O
critical O
organ O
, O
but O
resulting O
in O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Hb I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
and/or O
transfusion O
of O
> O
=2 O
units O
of O
whole O
blood O
or O
packed O
red O
blood O
cells O
] O
27 O
( O
0.7 O
) O
37 O
( O
0.9 O
) O
Decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Hb I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
28 O
( O
0.7 O
) O
42 O
( O
1.0 O
) O
Transfusion O
of O
> O
=2 O
units O
of O
whole O
blood O
or O
packed O
red O
blood O
cells O
18 O
( O
0.4 O
) O
25 O
( O
0.6 O
) O
Clinically O
relevant O
non-major O
bleeding B-OSE_Labeled_AE
357 O
( O
8.6 O
) O
357 O
( O
8.7 O
) O
Any O
bleeding B-OSE_Labeled_AE
1169 O
( O
28.3 O
) O
1153 O
( O
28.0 O
) O
Reduction O
in O
the O
Risk O
of O
Recurrence O
of O
DVT O
and/or O
PE O
EINSTEIN O
CHOICE O
Study O
In O
the O
EINSTEIN O
CHOICE O
clinical O
study O
, O
the O
most O
frequent O
adverse O
reactions O
associated O
with O
permanent O
drug O
discontinuation O
were O
bleeding B-OSE_Labeled_AE
events O
, O
with O
incidence O
rates O
of O
1 O
% O
for O
XARELTO O
10 O
mg O
, O
2 O
% O
for O
XARELTO O
20 O
mg O
, O
and O
1 O
% O
for O
acetylsalicylic O
acid O
( O
aspirin O
) O
100 O
mg O
. O

The O
mean O
duration O
of O
treatment O
was O
293 O
days O
for O
XARELTO O
10 O
mg-treated O
patients O
and O
286 O
days O
for O
aspirin O
100 O
mg-treated O
patients O
. O

Table O
3 O
shows O
the O
number O
of O
patients O
experiencing O
bleeding B-NonOSE_AE
events O
in O
the O
EINSTEIN O
CHOICE O
study O
. O

Table O
3 O
: O
Bleeding O
EventsBleeding O
event O
occurred O
after O
the O
first O
dose O
and O
up O
to O
2 O
days O
after O
the O
last O
dose O
of O
study O
drug O
. O

Although O
a O
patient O
may O
have O
had O
2 O
or O
more O
events O
, O
the O
patient O
is O
counted O
only O
once O
in O
a O
category O
. O

in O
EINSTEIN O
CHOICE O
Parameter O
XARELTO O
[ O
note O
: O
Treatment O
schedule O
: O
XARELTO O
10 O
mg O
once O
daily O
or O
aspirin O
100 O
mg O
once O
daily O
. O
] O

10 O
mgN=1127n O
( O
% O
) O
Acetylsalicylic O
Acid O
( O
aspirin O
) O
100 O
mgN=1131n O
( O
% O
) O
Major O
bleeding B-OSE_Labeled_AE
event O
5 O
( O
0.4 O
) O
3 O
( O
0.3 O
) O
Fatal O
bleeding B-OSE_Labeled_AE
0 O
1 O
( O
< O
0.1 O
) O
Non-fatal O
critical O
organ O
bleeding B-OSE_Labeled_AE
2 O
( O
0.2 O
) O
1 O
( O
< O
0.1 O
) O
Non-fatal O
non-critical O
organ O
bleeding B-OSE_Labeled_AE
[ O
note O
: O
Major O
bleeding B-OSE_Labeled_AE
which O
is O
not O
fatal O
or O
in O
a O
critical O
organ O
, O
but O
resulting O
in O
a O
decrease B-OSE_Labeled_AE
in I-OSE_Labeled_AE
Hb I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
g I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
and/or O
transfusion O
of O
> O
= O
2 O
units O
of O
whole O
blood O
or O
packed O
red O
blood O
cells O
. O
] O

3 O
( O
0.3 O
) O
1 O
( O
< O
0.1 O
) O
Clinically O
relevant O
non-major O
( O
CRNM O
) O
bleeding B-OSE_Labeled_AE
[ O
note O
: O
Bleeding B-OSE_Labeled_AE
which O
was O
clinically O
overt O
, O
did O
not O
meet O
the O
criteria O
for O
major O
bleeding B-NonOSE_AE
, O
but O
was O
associated O
with O
medical O
intervention O
, O
unscheduled O
contact O
with O
a O
physician O
, O
temporary O
cessation O
of O
treatment O
, O
discomfort O
for O
the O
patient O
, O
or O
impairment B-NonOSE_AE
of I-NonOSE_AE
activities I-NonOSE_AE
of I-NonOSE_AE
daily I-NonOSE_AE
life I-NonOSE_AE
. O
] O

22 O
( O
2.0 O
) O
20 O
( O
1.8 O
) O
Any O
bleeding B-OSE_Labeled_AE
151 O
( O
13.4 O
) O
138 O
( O
12.2 O
) O
In O
the O
EINSTEIN O
CHOICE O
study O
, O
there O
was O
an O
increased O
incidence O
of O
bleeding B-OSE_Labeled_AE
, O
including O
major O
and O
CRNM O
bleeding B-OSE_Labeled_AE
in O
the O
XARELTO O
20 O
mg O
group O
compared O
to O
the O
XARELTO O
10 O
mg O
or O
aspirin O
100 O
mg O
groups O
. O

Prophylaxis O
of O
Deep O
Vein O
Thrombosis O
Following O
Hip O
or O
Knee O
Replacement O
Surgery O
In O
the O
RECORD O
clinical O
trials O
, O
the O
overall O
incidence O
rate O
of O
adverse O
reactions O
leading O
to O
permanent O
treatment O
discontinuation O
was O
3.7 O
% O
with O
XARELTO O
. O

The O
rates O
of O
major O
bleeding B-NonOSE_AE
events O
and O
any O
bleeding B-NonOSE_AE
events O
observed O
in O
patients O
in O
the O
RECORD O
clinical O
trials O
are O
shown O
in O
Table O
4 O
. O

Table O
4 O
: O
Bleeding O
EventsBleeding O
events O
occurring O
any O
time O
following O
the O
first O
dose O
of O
double-blind O
study O
medication O
( O
which O
may O
have O
been O
prior O
to O
administration O
of O
active O
drug O
) O
until O
two O
days O
after O
the O
last O
dose O
of O
double-blind O
study O
medication O
. O

Patients O
may O
have O
more O
than O
one O
event O
. O

in O
Patients O
Undergoing O
Hip O
or O
Knee O
Replacement O
Surgeries O
( O
RECORD O
1-3 O
) O
XARELTO O
10 O
mg O
Enoxaparin O
[ O
note O
: O
Includes O
the O
placebo-controlled O
period O
for O
RECORD O
2 O
, O
enoxaparin O
dosing O
was O
40 O
mg O
once O
daily O
( O
RECORD O
1-3 O
) O
] O
Total O
treated O
patients O
N=4487n O
( O
% O
) O
N=4524n O
( O
% O
) O
Major O
bleeding B-OSE_Labeled_AE
event O
14 O
( O
0.3 O
) O
9 O
( O
0.2 O
) O
Fatal O
bleeding B-OSE_Labeled_AE
1 O
( O
< O
0.1 O
) O
0 O
Bleeding B-OSE_Labeled_AE
into O
a O
critical O
organ O
2 O
( O
< O
0.1 O
) O
3 O
( O
0.1 O
) O
Bleeding B-OSE_Labeled_AE
that O
required O
re-operation O
7 O
( O
0.2 O
) O
5 O
( O
0.1 O
) O
Extra-surgical O
site O
bleeding B-OSE_Labeled_AE
requiring O
transfusion O
of O
> O
2 O
units O
of O
whole O
blood O
or O
packed O
cells O
4 O
( O
0.1 O
) O
1 O
( O
< O
0.1 O
) O
Any O
bleeding B-OSE_Labeled_AE
event O
[ O
note O
: O
Includes O
major O
bleeding B-OSE_Labeled_AE
events O
] O
261 O
( O
5.8 O
) O
251 O
( O
5.6 O
) O
Hip O
Surgery O
Studies O
N=3281n O
( O
% O
) O
N=3298n O
( O
% O
) O
Major O
bleeding B-OSE_Labeled_AE
event O
7 O
( O
0.2 O
) O
3 O
( O
0.1 O
) O
Fatal O
bleeding B-OSE_Labeled_AE
1 O
( O
< O
0.1 O
) O
0 O
Bleeding B-OSE_Labeled_AE
into O
a O
critical O
organ O
1 O
( O
< O
0.1 O
) O
1 O
( O
< O
0.1 O
) O
Bleeding B-OSE_Labeled_AE
that O
required O
re-operation O
2 O
( O
0.1 O
) O
1 O
( O
< O
0.1 O
) O
Extra-surgical O
site O
bleeding B-OSE_Labeled_AE
requiring O
transfusion O
of O
> O
2 O
units O
of O
whole O
blood O
or O
packed O
cells O
3 O
( O
0.1 O
) O
1 O
( O
< O
0.1 O
) O
Any O
bleeding B-OSE_Labeled_AE
event O
201 O
( O
6.1 O
) O
191 O
( O
5.8 O
) O
Knee O
Surgery O
Study O
N=1206n O
( O
% O
) O
N=1226n O
( O
% O
) O
Major O
bleeding B-OSE_Labeled_AE
event O
7 O
( O
0.6 O
) O
6 O
( O
0.5 O
) O
Fatal O
bleeding B-OSE_Labeled_AE
0 O
0 O
Bleeding B-OSE_Labeled_AE
into O
a O
critical O
organ O
1 O
( O
0.1 O
) O
2 O
( O
0.2 O
) O
Bleeding B-OSE_Labeled_AE
that O
required O
re-operation O
5 O
( O
0.4 O
) O
4 O
( O
0.3 O
) O
Extra-surgical O
site O
bleeding B-OSE_Labeled_AE
requiring O
transfusion O
of O
> O
2 O
units O
of O
whole O
blood O
or O
packed O
cells O
1 O
( O
0.1 O
) O
0 O
Any O
bleeding B-OSE_Labeled_AE
event O
60 O
( O
5.0 O
) O
60 O
( O
4.9 O
) O
Following O
XARELTO O
treatment O
, O
the O
majority O
of O
major O
bleeding B-OSE_Labeled_AE
complications O
( O
> O
=60 O
% O
) O
occurred O
during O
the O
first O
week O
after O
surgery O
. O

Other O
Adverse O
Reactions O
Non B-NonOSE_AE
- I-NonOSE_AE
hemorrhagic I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
reported O
in O
> O
=1 O
% O
of O
XARELTO-treated O
patients O
in O
the O
EINSTEIN O
DVT B-Not_AE_Candidate
and O
EINSTEIN O
PE B-Not_AE_Candidate
studies O
are O
shown O
in O
Table O
5 O
. O

Table O
5 O
: O
Other O
Adverse O
ReactionsAdverse O
reaction O
with O
Relative O
Risk O
> O
1.5 O
for O
XARELTO O
versus O
comparator O
Reported O
by O
> O
=1 O
% O
of O
XARELTO-Treated O
Patients O
in O
EINSTEIN O
DVT O
and O
EINSTEIN O
PE O
Studies O
Body O
SystemAdverse O
Reaction O
EINSTEIN O
DVT B-Not_AE_Candidate
Study O
XARELTO O
20 O
mgN=1718n O
( O
% O
) O
Enoxaparin/VKAN=1711n O
( O
% O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
46 O
( O
2.7 O
) O
25 O
( O
1.5 O
) O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
24 O
( O
1.4 O
) O
15 O
( O
0.9 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
50 O
( O
2.9 O
) O
31 O
( O
1.8 O
) O
Muscle B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
23 O
( O
1.3 O
) O
13 O
( O
0.8 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
38 O
( O
2.2 O
) O
22 O
( O
1.3 O
) O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
24 O
( O
1.4 O
) O
11 O
( O
0.6 O
) O
Depression B-OSE_Labeled_AE
20 O
( O
1.2 O
) O
10 O
( O
0.6 O
) O
Insomnia B-OSE_Labeled_AE
28 O
( O
1.6 O
) O
18 O
( O
1.1 O
) O
EINSTEIN O
PE B-Not_AE_Candidate
Study O
XARELTO O
20 O
mgN=2412n O
( O
% O
) O
Enoxaparin/VKAN=2405n O
( O
% O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
53 O
( O
2.2 O
) O
27 O
( O
1.1 O
) O
Non B-NonOSE_AE
- I-NonOSE_AE
hemorrhagic I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
reported O
in O
> O
=1 O
% O
of O
XARELTO-treated O
patients O
in O
RECORD O
1-3 O
studies O
are O
shown O
in O
Table O
6 O
. O

Table O
6 O
: O
Other O
Adverse O
Drug O
ReactionsAdverse O
reaction O
occurring O
any O
time O
following O
the O
first O
dose O
of O
double-blind O
medication O
, O
which O
may O
have O
been O
prior O
to O
administration O
of O
active O
drug O
, O
until O
two O
days O
after O
the O
last O
dose O
of O
double-blind O
study O
medication O
Reported O
by O
> O
=1 O
% O
of O
XARELTO-Treated O
Patients O
in O
RECORD O
1-3 O
Studies O
Body O
SystemAdverse O
Reaction O
XARELTO10 O
mgN=4487n O
( O
% O
) O
Enoxaparin O
[ O
note O
: O
Includes O
the O
placebo-controlled O
period O
of O
RECORD O
2 O
, O
enoxaparin O
dosing O
was O
40 O
mg O
once O
daily O
( O
RECORD O
1-3 O
) O
] O
N=4524n O
( O
% O
) O
Injury B-NonOSE_AE
, I-NonOSE_AE
poisoning I-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Wound B-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
125 O
( O
2.8 O
) O
89 O
( O
2.0 O
) O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
74 O
( O
1.7 O
) O
55 O
( O
1.2 O
) O
Muscle B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
52 O
( O
1.2 O
) O
32 O
( O
0.7 O
) O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Syncope B-OSE_Labeled_AE
55 O
( O
1.2 O
) O
32 O
( O
0.7 O
) O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Pruritus B-OSE_Labeled_AE
96 O
( O
2.1 O
) O
79 O
( O
1.8 O
) O
Blister B-OSE_Labeled_AE
63 O
( O
1.4 O
) O
40 O
( O
0.9 O
) O
Other O
clinical O
trial O
experience O
: O
In O
an O
investigational O
study O
of O
acute O
medically O
ill O
patients O
being O
treated O
with O
XARELTO O
10 O
mg O
tablets O
, O
cases O
of O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
with O
bronchiectasis B-OSE_Labeled_AE
were O
observed O
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
XARELTO O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
agranulocytosis B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
: O
retroperitoneal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
jaundice B-OSE_Labeled_AE
, O
cholestasis B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
( O
including O
hepatocellular B-OSE_Labeled_AE
injury I-OSE_Labeled_AE
) O
Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
hypersensitivity B-OSE_Labeled_AE
, O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
, O
angioedema B-OSE_Labeled_AE
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
cerebral B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
subdural B-OSE_Labeled_AE
hematoma I-OSE_Labeled_AE
, O
epidural B-OSE_Labeled_AE
hematoma I-OSE_Labeled_AE
, O
hemiparesis B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE

